For the year ending 2025-12-31, ALDX had $15,514,162 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -33,846,661 |
| Stock-based compensation | 6,091,413 |
| Non-cash interest expense | 218,260 |
| Net amortization of premium on marketable securities | 1,149,550 |
| Depreciation and amortization expense | 251,993 |
| Write-off of deferred offering costs | 267,261 |
| Prepaid expenses and other current assets | -1,179,004 |
| Accounts payable | -21,992 |
| Accrued expenses and other liabilities | -6,335,410 |
| Net cash used in operating activities | -33,345,682 |
| Purchases of marketable securities | 40,263,712 |
| Maturities of marketable securities | 88,000,000 |
| Net cash provided by (used in) investing activities | 47,736,288 |
| Issuance costs | 0 |
| Proceeds from exercise of stock options | 1,103,940 |
| Proceeds from employee stock purchase plan | 19,616 |
| Debt end of term charge paid in cash | 0 |
| Net cash provided by (used in) financing activities | 1,123,556 |
| Net increase (decrease) in cash and cash equivalents | 15,514,162 |
| Cash and cash equivalents, beginning of period | 54,527,092 |
| Cash and cash equivalents, end of period | 70,041,254 |
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)